Table 1.
Comparison of marketed PDE5-Is
| Property | Sildenafil | Vardenafil | Tadalafil | Avanafil |
|---|---|---|---|---|
| Year of first market authorization | 1998 | 2003 | 2003 | 2013 |
| Generation | First | First | First | Second |
| Absorption and elimination | Relatively rapid; medium half-life | Relatively rapid; medium half-life | Relatively slow; long half-life | Rapid; relatively long half-life |
| Formulations available | Film-coated tablet, ODT, ODF | Film-coated tablet, ODT | Film-coated tablet | Film-coated tablet |
| Marketed dosages | ||||
| Conventional tablets | 25, 50, 100 mg | 5, 10, 20 mg | 2.5, 5, 10, 20 mg | 50, 100, 200 mg |
| ODF | 25, 50, 75, 100 mg | 10 mg | ||
| Common adverse reactions | Headache, flushing, dyspepsia, nasal congestion, naso-pharyngitis, visual abnormalities | Headache, flushing, dyspepsia, nasal congestion, naso-pharyngitis, visual abnormalities | Headache, flushing, dyspepsia, nasal congestion, back pain, naso-pharyngitis, visual abnormalities | Headache, flushing, dyspepsia, nasal congestion, naso-pharyngitis |
ODF = orodispersible film; ODT = orodispersible tablet; PDE5-Is = phosphodiesterase type 5 inhibitors.